XML 10 R4.htm IDEA: XBRL DOCUMENT v3.25.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Total revenue $ 860.5 $ 864.4 $ 2,459.3 $ 2,386.8
Total cost of revenue 481.1 445.6 1,330.8 1,230.6
Gross profit 379.4 418.8 1,128.5 1,156.2
Operating expenses:        
Selling, general and administrative 242.5 229.9 699.3 646.5
Research and development 98.3 98.1 295.6 272.1
Goodwill impairment charge 96.5 0.0 96.5 0.0
Other (gains) charges, net (6.1) 22.7 45.2 56.6
Total operating expenses 431.2 350.7 1,136.6 975.2
Operating (loss) income (51.8) 68.1 (8.1) 181.0
Interest and other (expense), net (20.0) (12.8) (38.1) (30.2)
(Loss) income before income taxes, equity in income (losses) of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries (71.8) 55.3 (46.2) 150.8
Income tax (benefit) provision (14.1) 14.8 (8.5) 50.7
Equity in (losses) income of unconsolidated investees, net of tax (0.8) (0.2) 0.2 (0.2)
Consolidated net (loss) income (58.5) 40.3 (37.5) 99.9
Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries 1.1 (0.6) (2.9) 0.5
Net (loss) income attributable to Bruker Corporation (59.6) 40.9 (34.6) 99.4
Dividends on Series A Mandatory Convertible Preferred Stock 2.8 0.0 2.8 0.0
Net (loss) income attributable to Bruker Corporation common shareholders $ (62.4) $ 40.9 $ (37.4) $ 99.4
Net (loss) income per common share attributable to Bruker Corporation common shareholders:        
Basic $ (0.41) $ 0.27 $ (0.25) $ 0.67
Diluted $ (0.41) $ 0.27 $ (0.25) $ 0.67
Weighted average common shares outstanding:        
Basic 151.8 151.5 151.7 148.1
Diluted 151.8 152.0 151.7 148.7
Product        
Total revenue $ 691.1 $ 709.3 $ 1,969.1 $ 1,950.6
Total cost of revenue 389.0 349.3 1,057.4 967.0
Service and other revenue        
Total revenue 169.4 155.1 490.2 436.2
Total cost of revenue $ 92.1 $ 96.3 $ 273.4 $ 263.6